Results 101 to 110 of about 5,449 (190)

Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol

Scientific Reports
Klebsiella pneumoniae carbapenemase (KPC) is a frequent and widespread carbapenemase, with over 260 variants identified. While KPC often evolves resistance to ceftazidime-avibactam, cefiderocol remains a key treatment option.
Sidonie Hanna, Kevin La, Yutaka Yoshii, Maud Gits-Muselli, Imane El Meouche, Yasmine Benhadid-brahmi, Stéphane Bonacorsi, André Birgy   +7 more
doaj   +1 more source

Impact of medium composition on cefiderocol susceptibility testing: comparison of CLSI/EUCAST-compliant and commercial broth microdilution methods. [PDF]

JAC Antimicrob Resist
Turowski P, Pfennigwerth N, Gatermann SG.   +2 more
europepmc   +1 more source

A case of prolonged cefiderocol therapy during continuous hemodiafiltration in a patient with an implanted left ventricular assist device. [PDF]

IDCases
Kimura H, Yano T, Kurokawa Y, Murakami S, Miyamoto H, Hidaka N, Tauchi H, Tanaka M.   +7 more
europepmc   +1 more source

<i>Stenotrophomonas maltophilia</i> in the Antimicrobial Resistance Era: Species-Complex Taxonomy, Pathogenesis, Evolving Therapeutic Priorities, and Genomic Surveillance. [PDF]

Infect Drug Resist
Sun R, Cao X, Sun Q.
europepmc   +1 more source

Emergence of a novel NDM-4-producing <i>Citrobacter freundii</i> complex species in a complicated urinary tract infection treated with cefiderocol. [PDF]

IDCases
Boehm C, Dingle TC, Croxen MA, Lynch T, Church D.   +4 more
europepmc   +1 more source

Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]

J Antimicrob Chemother
Sader HS, Papp-Wallace KM, Kimbrough JH, Debabov D, Mendes RE, Castanheira M.   +5 more
europepmc   +1 more source

<i>In vitro</i> activity and clinical use of cefiderocol against <i>Achromobacter xylosoxidans</i> (Review). [PDF]

Biomed Rep
Giovagnorio F, Colpani A, De Vito A, Marino A, Madeddu G, Nunnari G, Di Bella S, Geremia N.   +7 more
europepmc   +1 more source

Human ex vivo comparison of Escherichia coli and Pseudomonas aeruginosa lipopolysaccharide-induced immune responses and cefiderocol effects in whole blood. [PDF]

Med Microbiol Immunol
Pracher L, Jorda A, Eberl S, Weber M, Zeitlinger M.   +4 more
europepmc   +1 more source

Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1. [PDF]

J Antimicrob Chemother
Raro OHF, Mancini S, Findlay J, Seth-Smith HMB, Ali Syed M, Egli A, Nordmann P, Poirel L.   +7 more
europepmc   +1 more source

Reduced Susceptibility to Cefiderocol Among Clinical MCR-1-Producing <i>Escherichia coli</i> Isolates from Tunisia. [PDF]

Antibiotics (Basel)
Jaidane N, Naas T, Fayad S, Châtre P, Mansour W, Bouaziz A, François P, Fraysseix LD, Iorga BI, Al Laham NA, Tilouche L, Barguellil F, Haenni M.   +12 more
europepmc   +1 more source